for the Post-marketing Surveillance Team M Objective: Post-marketing surveillance was conducted to monitor the performance of the OraQuick Advance rapid HIV-1/2 antibody test (OraQuick) on whole blood and oral fluid. Design: Surveillance of routinely collected data on clients tested with OraQuick in 368 testing sites affiliated with 17 state and city health departments between 11 August 2004 and 30 June 2005.
Introduction
Approximately 24-27% of the 1 039 000-1 185 000 persons in the United States living with HIV do not know their serostatus [1] . The Advancing HIV Prevention initiative, introduced by the Centers for Disease Control and Prevention (CDC) in 2003, aims to reduce the number of HIV-infected persons who are unaware of their status [2] . As part of this initiative, CDC purchased and distributed OraQuick Advance rapid HIV-1/2 antibody tests (OraQuick) to health departments and community-based organizations, and conducted postmarketing surveillance to monitor the product's performance. OraQuick was the first rapid HIV test waived under the Clinical Laboratory Improvement Amendments of 1988 for use at point of care [3] . It can be used by trained operators in non-clinical settings on whole blood and oral fluid. The manufacturer's specificity claim for whole blood is 100% (95% confidence interval (CI): 99.7-100%) and 99.8% for oral fluid (95% CI: 99.6-99.9%) [4] . In this paper, we describe the whole blood and oral fluid specificity and positive predictive value of OraQuick at health departments that conducted surveillance, and the outcomes of an investigation at one site that reported excess oral fluid false-positive tests.
Methods Design
Health departments in three cities (Chicago, New York City and San Francisco) and 14 states (Arizona, Delaware, Florida, Indiana, Louisiana, Massachusetts, Michigan, Montana, Nebraska, New Jersey, New York, North Carolina, Utah and Wisconsin) selected rapid test sites in their jurisdictions to participate in post-marketing surveillance. Whole blood and oral fluid OraQuick tests conducted at 368 sites between 11 August 2004 and 30 June 2005 were included in surveillance. Specimens from clients with reactive rapid tests were submitted to local laboratories for Western blot (WB) or indirect immunofluorescence (IFA) confirmation. Clients with discordant results (e.g. those who had a reactive rapid test not confirmed positive by WB or IFA) were asked to return for follow-up testing 4 weeks after their initial test [5] . Demographic data and HIV test results were entered into local health department data systems. Electronic data were submitted to CDC in accordance with variable maps designed to create one standard dataset.
Definitions
Non-reactive OraQuick tests were assumed to be true negatives. A true positive was defined as a reactive OraQuick test followed by a positive WB or IFA. Initially discordant results were reclassified as: (1) true positive if the follow-up WB or IFA was positive or the client had a detectable viral load; (2) false positive if the last follow-up confirmatory tests was negative or if no record of followup testing was obtained; and (3) indeterminate if the last WB or IFA was indeterminate. Specificity was defined as the number of negative tests divided by the sum of negative and false-positive tests. Positive predictive value (PPV) was defined as the number of true-positive tests divided by the sum of true-positive plus falsepositive tests.
Analyses
For each health department, we report the number of participating sites and the following outcomes by specimen type: the number of negative and true-positive tests, percent seropositivity, number of false-positive tests, specificity and PPV. Exact confidence intervals were calculated for specificity using the Clopper-Pearson method [6] . The median (range) seropositivity, specificity and PPV for the 17 health departments were also calculated. Specificity was compared with the manufacturer's claim for whole blood and oral fluid [4] . Statistical comparisons were made using the chi-square test. All analyses were conducted using SAS (Statistical Application Software v9.1, SAS Institute Inc., Cary, North Carolina, USA). Technologies conducted an investigation to assess whether device expiration, manufacturing lot, operator practices, device-storage or testing-area temperatures might have been associated with these false-positive tests. As part of our investigation of excess false-positive tests, we report the seropositivity, specificity and PPV for site X by month. We also compare the specificity of oral fluid OraQuick at site X with 11 other rapid test sites in San Francisco from March to November 2005.
Human subjects
Surveillance activities and investigations were conducted as part of post-marketing surveillance determined at CDC to be non-research.
Results
Surveillance population characteristics A total of 162 317 OraQuick tests were conducted at the 368 sites. Of these, 29.5% were conducted at counseling and testing sites, 29.0% at sexually transmitted disease (STD) clinics, and 17.7% at correctional facilities; 63.8% were conducted on males, 50.0% on clients 29 years of age, and 41.7% on clients who were black, 39.8% white, 17.4% Hispanic, 2.1% Asian, 1.3% American Indian/ Alaskan Natives, and 0.3% Native Hawaiian or other Pacific Islander. Of the OraQuick tests, 135 724 (83.6%) were conducted on whole blood, 26 066 (16.1%) on oral fluid, and 527 (0.3%) on an unrecorded specimen type.
Discordant results
A total of 124 initially discordant results were reported; 68 (0.05%) of 135 724 whole blood rapid tests, and 56 (0.22%) of 26 066 oral fluid rapid tests. Of the 68 discordant whole blood results, 13 (19.1%) were classified as true positive, 15 (22.1%) as indeterminate and 40 (58.8%) as false positive. Of the 56 discordant oral fluid results, 4 (7.1%) were classified as true positive, 5 (8.9%) as indeterminate and 47 (83.9%) as false positive. Of discordant results that were classified as false positive, a similar proportion of false-positive whole blood versus false-positive oral fluid results were based on !1 followup tests (52.5 versus 38.3%, P ¼ 0.18).
Seropositivity, specificity, positive predictive value
The median HIV seropositivity was 0.83% (range among 17 health departments: 0.08-2.60%) among tests conducted using whole blood and 1.00% (range: 0-4.02%) among tests conducted using oral fluid. The median specificity was 99.98% (range: 99.73-100%) for whole blood and 99.89% (range: 99.44-100%) for oral fluid. The median PPV was 99.24% (range: 66.67-100%) for whole blood and 90.00% (range: 50.00-100%) for oral fluid. Point estimates for whole blood specificity at all health departments exceeded 99.7%, the lower bound of the 95% confidence interval of the manufacturer's specificity claim [4] . Point estimates for oral fluid specificity at all health departments except one (Arizona) exceeded 99.6% (Table 1) . At this health department, the upper bound of the 95% CI for oral-fluid specificity overlaps the lower bound of the 95% CI of the manufacturer's claim ( Table 1) .
Investigation of excess oral fluid false-positive tests
Specificity and positive predictive value At site X in San Francisco, of 2585 oral fluid OraQuick tests conducted, one was invalid and 33 (1.3%) were classified as false positive (11 of the 33 did not have follow-up testing). The oral fluid specificity at this site fell below the manufacturer's claim and was significantly lower than 11 other sites in San Francisco ( Table 2 ). The number of false-positive oral fluid tests increased from July through October (Fig. 1 ). Because of staff concerns, the site discontinued use of oral fluid OraQuick on 16 November 2005.
Device characteristics
The 33 false-positive OraQuick tests at site X were from unexpired devices from four lots: 17 (51.5%) from one lot, 13 (39.4%) from a second, 2 (6.1%) from a third and 1 (3.0%) from a fourth. Each of these lots was used at other sites in San Francisco. Of the 33 devices with false-positive results, 29 (87.9%) had test lines (lines that denote a preliminary positive result) that were qualitatively described as 'gray', 'extremely faint' or 'shadowy'.
Operator practices
Seven primary operators at site X performed and interpreted the 33 false-positive OraQuick tests within 20-40 min. One operator read 14 (42.4%) devices, one read eight (24.2%), one read seven (21.2%) and four read one each (12.0%). In all 33 cases, the test line was read by more than one operator before the preliminary positive result was given to the client. Operator practices were observed to be in accordance with the package insert, with the exception of oral fluid specimen collection (some operators recommended that clients swab the upper and lower gum lines more than once with the OraQuick device). Operators were retrained on oral fluid specimen collection practices in October. Thirteen (39.4%) of the 33 false-positive results occurred after this retraining.
External controls and temperatures
From March through November 2005, staff performed 163 (6.3% of tests conducted) OraQuick external control runs at site X. Of these, two invalid results were observed; the remaining results were concordant with the negative or positive control. All temperatures recorded in storage and test logs during this period were within the manufacturer's specifications.
Discussion
From August 2004 through June 2005, surveillance of the OraQuick Advance rapid HIV-1/2 antibody test on over 150 000 clients in 17 health departments demonstrated that the device performed in accordance with manufacturer's specificity claim for use with both whole blood and oral fluid. Our findings support those from independent studies that found high OraQuick specificity for whole blood and oral fluid [7] [8] [9] . However, in accordance with the manufacturer's claim, we found that OraQuick specificity on oral fluid is slightly lower than that on whole blood [4] . Based on our observed median specificities, 11 false-positive results can be expected for every 10 000 oral fluid OraQuick tests performed on non-infected persons, and 2 false-positive results can be expected for every 10 000 whole blood OraQuick tests on non-infected persons.
Given the low HIV seropositivity observed in some health department sites, we were not surprised to find some low positive predictive values. The lower PPV for oral fluid than whole blood tests at some health departments resulted primarily from fewer HIVinfected persons who tested with oral fluid rather than from lower specificity of the oral fluid test. These findings underscore the importance that all persons who have a reactive rapid HIV test need to be informed that the positive result is preliminary and that confirmatory testing is necessary [10] . When the confirmatory test following a preliminary positive rapid test is not positive, current guidelines for follow-up testing should be heeded [5, 11] .
Post-marketing surveillance was subject to several limitations. First, health departments and rapid test sites were not randomly selected and some sites may have been 1664 AIDS 2006, Vol 20 No 12 selected to participate because of their prior experience with rapid testing or higher quality test performance. If true, our specificity estimates might be overestimates. It is unlikely, however, that OraQuick performance at test sites included in surveillance was very different than at sites that were not included. Approximately half of the 162 317 rapid tests were conducted by five health departments that included all of their rapid test sites in post-marketing surveillance. Also, the specificity at these five health departments was comparable with all other health departments. Second, false-positive designations were based on the Western blot and IFA, which are older assays and which might be less sensitive in identifying persons with recent infection compared with newer generation rapid tests [12] . However, additional diagnostic tests performed on the 87 clients with false-positive results indicate that HIV was not present. Remnant sera from clients with false-positive results were tested at CDC from initial confirmatory specimens (n ¼ 55) and from second confirmatory specimens (n ¼ 22) and all tests were non-reactive by third-generation enzyme immunoassay. Additionally, all 32 nucleic acid amplification tests conducted on specimens from the 87 clients with false-positive results had undetectable viral loads. These results were concordant with Western blot and IFA results on these clients.
We observed lower oral-fluid OraQuick specificity at site X compared with other sites in San Francisco. We did not identify a clear cause for the lower specificity at this one site. Manufacturing error seems an unlikely cause since the lots used at this site were used at other sites in San Francisco where an increase in whole blood false-positive tests did not occur. Although it is possible that the observed lower specificity at site X was a random event due to chance alone, the increase in false positives is probably attributed to one or more unmeasured site-specific operator or host factors. These factors may be sufficiently rare that they are difficult to identify.
One or more operators may have routinely overcollected oral fluid specimens by instructing clients to swab around the gums more than once, rather than once as recommended [4] . Although unknown, it is plausible that overcollection of oral fluid might result in higher concentrations of antibodies that either cross-react or bind non-specifically with antigen in the test strip. Also, increased saliva might affect dilution or flow through the test device. However, over one-third of the false-positive tests at site X occurred after operators were retrained on oral fluid collection, and operators generally performed the tests correctly when observed. The reported increase in false-positive tests at site X might also be attributed to differences in interpreting test results. In other rapid test sites, gray lines may be unrecognized by staff or classified as non-reactive or invalid. The manufacturer should consider modifying the package insert to clarify how gray lines should be interpreted [4] .
During post-marketing surveillance, whole blood and oral fluid OraQuick performed in the specificity range documented in the package insert. However, in one site, OraQuick specificity fell below this range during a specific time period. Operators who observe preliminary positive test results on whole blood or oral fluid specimens should continue to follow existing counseling and confirmatory testing guidelines [13] . If test providers observe an increase in false-positive OraQuick rapid HIV tests, they should notify the manufacturer, and assess adherence to package insert instructions and CDC quality assurance guidelines [4, 11] . 
